Creating new CRISPR tools for gene editing therapy
Developing novel Type 1 CRISPR tools for gene editing therapy
This study is working on new CRISPR tools to make gene editing safer and more precise for people with sickle cell disease, aiming to create better treatments with fewer risks.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Genetobe INC. NIH-funded |
| Lab location | 1 site (Ann Arbor, United States) |
| Project ID | NIH-10821108 on NIH RePORTER |
What this research studies
This research focuses on developing innovative CRISPR tools to enhance gene editing therapies, particularly for conditions like sickle cell disease. By exploring Type I CRISPR systems, the project aims to improve the precision and safety of gene editing, addressing limitations of current methods that rely on Cas9. The approach involves using non-double-strand break techniques to minimize potential damage to DNA, which could lead to safer treatments for patients. If successful, these advancements could pave the way for more effective therapies for genetic disorders.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals with genetic disorders, particularly those affected by sickle cell disease.
Not a fit: Patients with conditions not related to genetic disorders or those who do not have access to gene editing therapies may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to safer and more effective gene editing therapies for patients with genetic disorders like sickle cell disease.
How similar studies have performed: Previous research has shown promise in using CRISPR technology for gene editing, indicating that this approach could lead to significant advancements in treatment.
Where this research is happening
Ann Arbor, United States
- Genetobe INC. — Ann Arbor, United States (Active)
Researchers
- Principal investigator: Hou, Zhonggang — Genetobe INC.
- Study coordinator: Hou, Zhonggang
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.